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Abstract
Background
Children with acute lymphoblastic leukemia (ALL) often suffer from toxicity of chemothera-
peutic drugs such as Methotrexate (MTX). Previously, we reported that 20% of patients
receiving high-dose MTX developed oral mucositis. MTX inhibits folate metabolism, which is
essential for DNA methylation. We hypothesize that MTX inhibits DNA methylation, which
results into adverse effects. We studied DNA methylation markers during high-dose metho-
trexate treatment in pediatric acute lymphoblastic leukemia (ALL) in relation to developing
oral mucositis.
Materials & methods
S-Adenosyl-Methionine (SAM) and S-Adenosyl-Homocysteine (SAH) levels and LINE1
DNA methylation were measured prospectively before and after high-dose methotrexate
(HD-MTX 4 x 5g/m2) therapy in 82 children with ALL. Methotrexate-induced oral mucositis
was registered prospectively. Oral mucositis (grade 3 National Cancer Institute Criteria)
was used as clinical endpoint.
Results
SAM levels decreased significantly during methotrexate therapy (-16.1 nmol/L (-144.0 –
+46.0), p<0.001), while SAH levels and the SAM:SAH ratio did not change significantly.
LINE1 DNA methylation (+1.4% (-1.1 –+6.5), p<0.001) increased during therapy. SAM and
SAH levels were not correlated to LINE1 DNA methylation status. No association was found
between DNA methylation markers and developing oral mucositis.
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Conclusions
This was the first study that assessed DNA methylation in relation to MTX-induced oral
mucositis in children with ALL. Although global methylation markers did change during meth-
otrexate therapy, methylation status was not associated with developing oral mucositis.
Introduction
Treatment outcome of pediatric acute lymphoblastic leukemia (ALL) has improved substan-
tially over the past decades, with 5-year survival rates currently reaching 90% in developed
countries [1–3]. We previously showed that 20% of children with ALL receiving high-dose
MTX developed oral mucositis as an adverse effect despite folate rescue therapy [4]. It would
be of clinical value to identify predictors of MTX-induced oral mucositis to select patients who
could benefit from personalized intervention strategies [2].
MTX is an inhibitor of methionine-adenosine transferase (MAT), resulting in lower levels
of methionine with concomitant lower S-adenosyl-methionine (SAM) and is therefore
expected to decrease DNA methylation [5, 6]. In a mouse neural tube defect model, MTX
caused DNA hypomethylation [7]. In contrast, low-dose methotrexate caused global DNA
hypermethylation in rheumatoid arthritis patients [8, 9]. DNA methylation is the process in
which methyl-groups (-CH3) bind to Cytosine-phosphate-Guanine dinucleotides (CpG) in the
DNA, by which it plays a role in ‘gene-silencing’ [10]. Methyl-groups are obtained from one-
carbon metabolism, during which the methyl-group from SAM is donated to DNA, RNA and
proteins, after which S-adenosyl-homocysteine (SAH) is formed (Fig 1). Plasma SAM and
SAH metabolite levels and the SAM:SAH ratio reflect the global intracellular methylation sta-
tus of the cell. Disturbances in SAM—SAH levels in combination with a decreased SAM:SAH
ratio are associated with DNA hypomethylation [11]. Global DNA methylation status can be
Fig 1. Role of MTX in relation to one-carbon metabolism. SAM: S-adenosylmethionine; SAH: S-
adenosylhomocysteine; DHF: dihydrofolate; THF: tetrahydrofolate; TS: thymidylate synthase; DHFR: dihydrofolate
reductase; MTHFD1: methylenetetrahydrofolate dehydrogenase 1; MTHFR: methylenetetrahydrofolate reductase;
MTX: methotrexate. Folic acid donates a methyl-group to the one-carbon metabolism pathway. Through several steps
methionine is transformed into SAM, which then donates the methyl-group for the DNA methylation process, and is
transformed into SAH and homocysteine. MTX inhibits DHFR and TS. By inhibiting DHFR, MTX inhibits the
pathway leading to methylation.
https://doi.org/10.1371/journal.pone.0199574.g001
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quantified by several methods, amongst which measuring DNA methylation status of Long
Interspersed Nuclear 1 elements (LINE1). LINE1 elements occur frequently (~20.000 copies)
in the human genome and DNA methylation status of these elements is therefore considered
to be a proxy for global DNA methylation [12].
Currently, no studies on changes in DNA methylation in relation to the development of
chemotherapy-related oral mucositis exist. However, DNA methylation has been implicated
as a possible biomarker of treatment-related toxicity in other malignancies and rheumathoid
arthritis treatment [13–16].
In the current prospective study we explored the hypothesis, that high-dose MTX therapy
inhibits global DNA methylation, which is associated with the development of MTX-induced
oral mucositis in children with ALL.
Materials & methods
Patients, treatment protocol and toxicity evaluation
The patient cohort and treatment protocol have been previously reported [4]. Briefly, patients
between 1 and 18 years treated according to the standard and medium risk arms of the Dutch
Childhood Oncology ALL-10 protocol (2004–2012) were eligible for the current study [17].
The study was approved by the Medical Ethical Committee (MEC-2005-358). Written
informed consent was obtained before data- and sample collection. An overview of protocol M
(HD-MTX phase; 5 gram/m2/course) is shown in S1 Fig. A modified version of The National
Cancer Institute (NCI) Common Terminology Criteria for Adverse Events v.3.0 score system
was used to score and document toxicity (S1 Table) [18]. Clinically relevant oral mucositis,
defined as NCI grade 3, was used as endpoint in the analyses [4]. The highest grade of toxic-
ity observed in each patient during protocol M was documented.
Sample collection
Peripheral EDTA blood samples were collected before the first HD-MTX course (T0) as well
as two weeks after discontinuation of protocol M (T1) and were stored at -80˚C (S1 Fig) [17].
DNA was isolated from whole blood using the MagNA Pure Compact Nucleid Acid isolation
kit (Roche Molecular Biochemicals1) according to the manufacturer’s instructions.
Cellular- and global DNA-methylation status
We measured plasma SAM and SAH levels as a proxy for cellular methylation status and
LINE1 DNA methylation as a proxy for global DNA methylation status at T0 and T1.
SAM and SAH plasma levels were measured using a liquid chromatography tandem-
mass spectrometry (LC-MS/MS) method using solid-phase extraction columns as previously
described [19]. The SAM:SAH ratio was calculated. The LINE1 global DNA methylation assay
was performed using primers as previously reported [20]. The LINE1 assay measured the
methylation percentage at 12 CpG sites. Primers were designed using EpiTYPER Designer
software (http://www.epidesigner.com/). We used a primer melting temperature of 64 ˚C, a
primer size of 25 bp and an amplicon length of 300 bp. Primer sequences are depicted in S2
Table.
For global LINE1 DNA methylation assay, isolated DNA (500 ng) was treated with sodium
bisulphite to discriminate between methylated and unmethylated cytosines using the EZ DNA
Methylation™ Kit (Zymo Research1) according to the manufacturer’s instructions. Bisulphite-
treated DNA was stored at +4˚C and processed within 1 week according to the manufacturer’s
instructions. The assay was performed in triplets per patient at T0 and T1 and mean DNA
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methylation values were calculated from these triplets when the variation coefficient was
<10%. A PCR to amplify bisulphite-treated DNA was performed using the C-1000 Touch
Thermal Cycler™ (Bio-Rad). Two μl of sodium bisulphite-treated DNA was added to each reac-
tion (total volume reaction: 12 μl). The PCR master mix consisted of 1.2 μl 10x Buffer, 1.2 μl
2mM deoxyribonucleotide triphosphates (dNTPs), 0.7 μl 25mM MgCl2, 2 μl of the forward
and reverse primer (1 pmol/μl), 0.1 μl AmpliTaq (5 U/L, Applied Biosystems, Waltham, MA,
USA) and 2.8 μl H2O. A standard ‘step-down’ PCR thermal cycling protocol was performed:
10 minutes at 95˚C; 5 cycles of 20 seconds (s) at 95˚C, 30 s at 65˚C and 1 minute at 72˚C; 5
cycles of 20 s at 95˚C, 30 s at 58˚C and 1 minute at 72˚C; 39 cycles of 20 s at 95˚C, 30 s at 53˚C,
1 minute at 72˚C and a final elongation step for 3 min at 72˚C followed by infinite hold at
12˚C. After the PCR, a dilution of 10 μl H2O, 3 μl PCR product and 2 μl loading dye was loaded
onto a 2% agarose gel to verify whether the PCR was successful. Unincorporated PCR primers
and deoxynucleotide triphosphates in the samples were inactivated by using shrimp alkaline
phosphatase (SAP) treatment as previously described [21]. Reverse transcription/RNase T
cleavage was performed using the following conditions: 3.21 μl of RNase-free double-distilled
H2O (ddH2O), 0.89 μl of 5x T7 polymerase buffer, 0.22 μl T Cleavage mix, 2.2 mM DTT, 20 U
T7 DNA & RNA polymerase and 0.6 μg RNase A in 2 μl of purified DNA product. This mix-
ture was incubated at 37˚C for 3 hours. Thereafter, 6 mg of Clean Resin and 20 μl of milliQ
H2O were added to each sample, rotated slowly for 20 minutes to mix reagents and then cen-
trifuged down for 5 minutes at 3000rpm. Thereafter, 10–15 nL of the cleavage reaction was dis-
pensed onto a SpectroCHIP array with a Nanodispenser RS1000 (Sequenom). The array was
performed on a Matrix-assisted Laser Desorption/Ionization—Time Of Flight (MALDI-TOF)
MassARRAY (Sequenom) analyzer according to the manufacturer’s instructions. LINE1
CpG4 could not be measured due to a silent signal. LINE1 CpG10 could not be analyzed due
to a low mass fragment. LINE1 CpG6 and 7, CpG8 and 9 and CpG11 and 12 were each ana-
lyzed together as the two CpG sites were present in one fragment. A precision experiment was
performed consisting of measuring 10 DNA controls, which should give DNA methylation
percentages with a variation coefficient of<10%.
Statistical analysis
Statistical analyses were performed using SPSS Statistics Version 20.0.0.1 (SPSS, Chicago, IL,
USA). For the LINE1 global DNA methylation assay the methylation percentage of individual
CpG sites and the mean methylation percentage of all CpG sites measured in the assays was
used for statistical analysis. Changes in SAM—SAH levels and the global LINE1DNA methyla-
tion status between T0 and T1 were tested using a paired T test (mean ± standard deviation) or
a Wilcoxon Rank Sum test (median, range), as appropriate, based on the normal distribution
of data. The association between SAM—SAH levels and global LINE1 DNA methylation
status at T0 and the change between T0 and T1 (delta T1 –T0) with the development of MTX-
induced oral mucositis was tested using an independent T test (mean ± standard deviation) or
a Mann Whitney U test (median, range) as appropriate. The correlation between SAM—SAH
levels and LINE1 DNA methylation was tested using a Spearman’s rho coefficient. A correla-
tion coefficient of>0.7 was considered relevant. In view of multiple comparisons the signifi-
cance level was set at a p-value of 0.004 using a Bonferroni correction (p-value = 0.05 / 12).
We tested the possible confounding effect of clinical characteristics (age at diagnosis, gender,
ALL immunophenotype, ALL risk group) by testing whether these factors were significantly
(p<0.05) related to both the determinant (DNA methylation) and the outcome (mucositis). If
confounders were significant in both these univariate analyses, they were included in a multi-
variate regression model.
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Results
Plasma SAM—SAH levels and LINE1 DNA methylation were measured before start of MTX
therapy (T0) and two weeks after end of MTX therapy (T1) in 82 pediatric ALL patients
(Table 1). LINE1 methylation percentages were measured at all CpG sites with a variation coef-
ficient of<10%. In total, 17 patients (21%) patients developed MTX-induced oral mucositis
NCI grade 3. Baseline characteristics are summarized in Table 1.
Methylation markers—Changes during MTX therapy
Methylation marker levels at T0 and T1 are described in Table 2. Plasma SAM levels were sig-
nificantly (mean -16.1 nmol/L [-144.0 –+46.0]) lower after MTX therapy (p-value < 0.001),
whereas SAH levels and SAM:SAH ratio did not change significantly (Table 2). LINE1 DNA
methylation increased (mean +1.4% [-1.1 –+6.5]) during MTX therapy (p-value <0.001,
Table 2 + S3 Table). SAM—SAH levels and LINE1 DNA methylation status at T0 and T1 were
not correlated (S4 Table).
Table 1. Baseline characteristics (n = 82).
Patient characteristics
Age at diagnosis
median (range in years) 5.4 (1–18)
Sex, n (%)
Female 46 (56)
Male 36 (44)
Immunophenotype ALL, n (%)
B-lineage 71 (87)
T-lineage 11 (13)
Risk group ALL-10 protocol, n(%)
Standard risk 23 (28)
Medium risk 59 (72)
Mucositis, n (%)
No 65 (79)
Yes 17 (21)
Clinically relevant mucositis is defined as grade 3 according to the National Cancer Criteria v.3.0. [18].
https://doi.org/10.1371/journal.pone.0199574.t001
Table 2. Methylation before and after stop of MTX therapy.
T0 (before start MTX) T1 (after stop MTX) p-value
Cellular methylation
SAM (nmol/L), median (range) (n = 77) 109.0 (71.0–245.0) 99.0 (44.0–151.0) <0.001
SAH (nmol/L), median (range) (n = 77) 13.5 (8.1–78.2) 12.9 (6.4–56.2) 0.234
SAM:SAH ratio, mean ± SD (n = 77) 8.0 ± 2.8 7.4 ± 3.1 0.207
Global DNA methylation
LINE1 –methylation (%), mean ± SD (n = 80) 65.1 ± 1.8 66.5 ± 1.9 <0.001
T0: before start MTX; T1: after stop MTX. Mean percentage methylation of CpG sites in LINE1 (%) and plasma SAM—SAH levels (nmol/L) at T0 vs. T1; mean ± SD or
median (range) based on normal distribution of data.
https://doi.org/10.1371/journal.pone.0199574.t002
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Methylation status in relation to MTX-induced oral mucositis
SAM and SAH levels and the SAM:SAH ratio at T0 were not associated with the occurrence of
MTX-induced oral mucositis (Table 3). LINE1 DNA methylation at T0 was not significantly
associated with the development of MTX-induced oral mucositis (Table 3 + S5 Table). In addi-
tion, changes in the methylation markers between T0 and T1 were not significantly associated
with the development of MTX-induced oral mucositis (Table 3 + S6 Table). None of the tested
clinical confounders (age at diagnosis, gender, ALL immunophenotype, ALL risk group) sig-
nificantly affected these analyses.
Discussion
This is the first study on the role of cellular methylation status and global DNA methylation in
relation to the development of MTX-induced oral mucositis in children with ALL. Although
we showed that global DNA methylation markers were changed after MTX therapy, plasma
SAM—SAH levels and LINE1 DNA methylation were not associated with developing oral
mucositis due to high-dose MTX treatment.
We observed a decrease in SAM levels after high-dose MTX treatment in pediatric ALL
patients, while the SAH levels and the SAM:SAH ratio did not show a significant change. This
very likely means that the change in SAM was not large enough to affect the SAM:SAH ratio
significantly. Inhibition of SAM levels has been shown previously in an in vitro methotrexate
model and a methotrexate-induced neural tube defect mouse model [7, 22]. Our study in the
pediatric ALL setting using a high-dose MTX regimen confirmed these results. However, this
decrease in SAM seen at the end of MTX therapy can also be caused by other factors, such as
environmental factors. More studies are necessary to assess the role of MTX in relation to
plasma SAM.
We observed small increases of 1–2% in LINE1 DNA methylation status after high-dose
MTX treatment, which are are in line with previous reports in other diseases [9, 23]. For
example, in patients using selective serotonin reuptake inhibitors, global and gene-specific
Table 3. SAM and SAH levels and LINE1 DNA methylation in relation to MTX-induced oral mucositis.
T0 p-value Change T0-T1 p-value
Cellular methylation
SAM (nmol/L), median (range) SAM (nmol/L), median (range)
No Mucositis n = 62 (78) 109.5 (72.0–245.0) 0.788 No Mucositis n = 62 (81) -12.5 (-144.0 –+46.0) 0.338
Mucositis n = 17 (22) 107.0 (71.0–151.0) Mucositis n = 15 (19) -9.0 (-46.0 –+31.0)
SAH (nmol/L), median (range) SAH (nmol/L), median (range)
No Mucositis n = 62 (78) 13.7 (8.1–58.8) 0.407 No Mucositis n = 62 (81) -1.0 (-33.8 –+46.0) 0.979
Mucositis n = 17 (22) 11.4 (6.3–78.2) Mucositis n = 15 (19) 0.4 (-53.6 –+11.1)
SAM:SAH ratio, mean ± SD SAM:SAH ratio, mean ± SD
No Mucositis n = 62 (78) 7.9 ± 2.8 0.405 No Mucositis n = 62 (81) -0.7 ± 3.6 0.501
Mucositis n = 17 (22) 8.6 ± 3.1 Mucositis n = 15 (19) 0.0 ± 3.3
Global DNA methylation
LINE1 –total methylation (%), mean
± SD
LINE1 –total methylation (%),
mean ± SD
No Mucositis n = 65 (79) 65.0 (± 1.9) 0.339 No Mucositis n = 63 (79) 1.5 ± 1.4 0.290
Mucositis n = 17 (21) 65.5 (± 1.3) Mucositis n = 17 (21) 1.1 ± 1.2
Mean percentage methylation of LINE1 and plasma SAM—SAH levels in nmol/L before start of MTX (T0) and the change (T0 –T1) during MTX therapy in relation to
MTX-induced oral mucositis; mean ± SD or median based on normal distribution of data.
https://doi.org/10.1371/journal.pone.0199574.t003
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methylation differences of 1–5% were found to be associated with treatment response [23].
Furthermore, 5-methylcytosine levels, which is another global DNA methylation measure, dif-
fered between healthy controls and rheumathoid arthritis patients receiving MTX with 1–2%
[9]. The observed increase in DNA methylation status after HD-MTX therapy should be repli-
cated in an independent case-control setting or validated using another global DNA methyla-
tion assay than the LINE1 assay to assess whether the observed changes are due to HD-MTX
and not due to other environmental factors, such as nutrition. The LINE1 hypermethylation
we found was contradictory to what we hypothesized, as MTX is expected to inhibit DNA
methylation. In line with our results, previous studies in rheumathoid arthritis patients showed
that MTX treatment induced DNA hypermethylation [8, 9].
A possible explanation for the observed DNA hypermethylation after MTX therapy in our
study is that concomitant therapy is administered, such as folate rescue therapy and 6-Mercap-
topurine. Folates provide methyl-groups necessary for methylation reactions and increased
DNA methylation status in several mouse tissues (liver, kidney, brain) as well as in peripheral
mononuclear cells [24, 25]. In contrast, 6-Mercaptopurine causes DNA hypomethylation [26].
It is possible that the inhibitory effect of MTX and 6-Mercaptopurine on DNA methylation
status is masked by folate rescue therapy, as folate increases DNA methylation status.
Our study showed no association between global methylation markers at start and at the
end of MTX therapy in relation to MTX-induced oral mucositis. These results do not confirm
the hypothesis that global methylation is associated with MTX-induced mucositis. However, a
recent study showed that the hypermethylation in CpG1 and CpG2 of the promotor of the ɣ-
Glutamyl Hydrolase (GGH) gene, which is involved in polyglutamating MTX, can signifi-
cantly reduce GGH mRNA expression in pediatric ALL [27]. Therefore, performing genome-
wide DNA methylation analyses using an Illumina methylation EPIC array could be relevant
in future studies to assess whether gene-specific DNA methylation status could be used as a
possible biomarker in predicting MTX-induced toxicity, such as oral mucositis.
Finally, in our study DNA methylation status was measured in DNA isolated from whole
blood leucocytes. At this point in therapy, patients are considered to be in complete remission,
and therefore the DNA methylation profile of leukemic blasts, which are known to be different
from normal leucocytes, should not interfere with our analysis. DNA methylation status differs
per tissue [28, 29]. In future studies, it would be interesting to look into DNA methylation
changes in the oral mucosa in relation to MTX-induced oral mucositis.
Strengths of our study are the prospective collection of toxicity data and the fact that all
patients were treated according to the same standardized treatment protocol. A limitation is
the relatively small sample size of this study.
Conclusion
This study is the first report to study methylation status in relation to the development of
MTX-induced oral mucositis in children with ALL. Global methylation markers changed after
high-dose MTX therapy, but we could not demonstrate that global methylation markers are
associated with the development of MTX-induced oral mucositis in pediatric ALL.
Supporting information
S1 Fig. Overview protocol M. Protocol M consists of a 57-day period in which patients receive
6-Mercaptopurine (6-MP) orally in a dose of 25 mg/m2/day. Patients receive 2-weekly high-
dose methotrexate (HD-MTX) intravenously in a dose of 5000 mg/m2/dose in 24 hours. Intra-
thecal infusions of methotrexate, cytarabine (ARA-C) and di-adreson F (DAF) are adminis-
tered 2-weekly. Leucovorin is administered at 36 hours, 42 hours and 48 hours after start of
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the HD-MTX infusion at a dose of 15 mg/m2/dose. Peripheral EDTA blood samples were
collected at day 1 of protocol M (T0)) as well as two weeks after discontinuation of protocol
M (T1).
(TIF)
S1 Table. National Cancer Institute (NCI) Criteria oral mucositis.
(DOCX)
S2 Table. Sequences of forward (F) and reverse (R) primers in bisulphite treated DNA.
(DOCX)
S3 Table. LINE1 DNA methylation status (percentage) at T0 and T1 per single CpG site.
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S4 Table. Correlation coefficients SAM, SAH, SAM/SAH ratio and LINE1.
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S5 Table. LINE1 DNA methylation status (percentage) at T0 in relation to MTX-induced
oral mucositis per single CpG site.
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S6 Table. Change in LINE1 DNA methylation status (Delta T1 –T0 percentage) during
MTX therapy in relation to MTX-induced oral mucositis per single CpG site.
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